Compass Therapeutics stock plunges on trial data concerns, William Blair comments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
Go back to Compass Therapeutics stock plunges on trial data concerns, William Blair comments
April 27, 2026 11:50 AM EDT
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $24.00 price target on Compass Therapeutics (NASDAQ: CMPX)
The analyst comments "What's next? The key question remains whether the FDA will accept PFS as the approvability anchor, along with the previously established ORR, or whether is will require OS. As the post-hoc non-crossover OS analysis was not pre-specified, the FDA may potentially scrutinize its usage.... More
April 27, 2026 10:20 AM EDT
Leerink Partners analyst Andrew Berens reiterated an Outperform rating and $11.00 price target on Compass Therapeutics (NASDAQ: CMPX).
The analyst comments "CMPX announced PFS and OS results for tovecimig in 2L BTC from the randomized COMPANION-002 study. At a high level, we view this data update as supportive of a path forward in an area of high unmet need. Recall, CMPX is evaluating tovecimig (CTX-009, DLL4xVEGF-A bispecific) + paclitaxel vs. paclitaxel in the Phase II/III COMPANION-002 study for 2L biliary tract cancer (BTC). In April 2025, CMPX announced that the study has met its... More
April 27, 2026 8:27 AM EDT
Stifel analyst Stephen Willey reiterated a Buy rating and $12.00 price target on Compass Therapeutics (NASDAQ: CMPX).
The analysdt comments "Secondary endpoint data from the P2/3 COMPANION-002 trial (paclitaxel ± tovecimig, 2L BTC) establishes a statistically-significant/clinicallymeaningful tovecimig-mediated improvement in mPFS (4.7 vs. 2.6 months, HR=0.44).... More
